用于心血管疾病一级和二级预防的纯素饮食模式。

Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases.

作者信息

Rees Karen, Al-Khudairy Lena, Takeda Andrea, Stranges Saverio

机构信息

Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.

Cochrane ENT, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

出版信息

Cochrane Database Syst Rev. 2021 Feb 25;2(2):CD013501. doi: 10.1002/14651858.CD013501.pub2.

Abstract

BACKGROUND

Diet plays a major role in the aetiology of cardiovascular disease (CVD) and as a modifiable risk factor is the focus of many prevention strategies. Recently vegan diets have gained popularity and there is a need to synthesise existing clinical trial evidence for their potential in CVD prevention.

OBJECTIVES

To determine the effectiveness of following a vegan dietary pattern for the primary and secondary prevention of CVD.

SEARCH METHODS

We searched the following electronic databases on 4 February 2020: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and Web of Science Core Collection. We also searched ClinicalTrials.gov in January 2021. We applied no language restrictions.

SELECTION CRITERIA

We selected randomised controlled trials (RCTs) in healthy adults and adults at high risk of CVD (primary prevention) and those with established CVD (secondary prevention). A vegan dietary pattern excludes meat, fish, eggs, dairy and honey; the intervention could be dietary advice, provision of relevant foods, or both. The comparison group received either no intervention, minimal intervention, or another dietary intervention. Outcomes included clinical events and CVD risk factors. We included only studies with follow-up periods of 12 weeks or more, defined as the intervention period plus post-intervention follow-up.

DATA COLLECTION AND ANALYSIS

Two review authors independently assessed studies for inclusion, extracted data and assessed risks of bias. We used GRADE to assess the certainty of the evidence. We conducted three main comparisons: 1. Vegan dietary intervention versus no intervention or minimal intervention for primary prevention; 2. Vegan dietary intervention versus another dietary intervention for primary prevention; 3. Vegan dietary intervention versus another dietary intervention for secondary prevention.

MAIN RESULTS

Thirteen RCTs (38 papers, 7 trial registrations) and eight ongoing trials met our inclusion criteria. Most trials contributed to primary prevention: comparisons 1 (four trials, 466 participants randomised) and comparison 2 (eight trials, 409 participants randomised). We included only one secondary prevention trial for comparison 3 (63 participants randomised). None of the trials reported on clinical endpoints. Other primary outcomes included lipid levels and blood pressure. For comparison 1 there was moderate-certainty evidence from four trials with 449 participants that a vegan diet probably led to a small reduction in total cholesterol (mean difference (MD) -0.24 mmol/L, 95% confidence interval (CI) -0.36 to -0.12) and low-density lipoprotein (LDL) cholesterol (MD -0.22 mmol/L, 95% CI -0.32 to -0.11), a very small decrease in high-density lipoprotein (HDL) levels (MD -0.08 mmol/L, 95% CI -0.11 to -0.04) and a very small increase in triglyceride levels (MD 0.11 mmol/L, 95% CI 0.01 to 0.21). The very small changes in HDL and triglyceride levels are in the opposite direction to that expected. There was a lack of evidence for an effect with the vegan dietary intervention on systolic blood pressure (MD 0.94 mmHg, 95% CI -1.18 to 3.06; 3 trials, 374 participants) and diastolic blood pressure (MD -0.27 mmHg, 95% CI -1.67 to 1.12; 3 trials, 372 participants) (low-certainty evidence). For comparison 2 there was a lack of evidence for an effect of the vegan dietary intervention on total cholesterol levels (MD -0.04 mmol/L, 95% CI -0.28 to 0.20; 4 trials, 163 participants; low-certainty evidence). There was probably little or no effect of the vegan dietary intervention on LDL (MD -0.05 mmol/L, 95% CI -0.21 to 0.11; 4 trials, 244 participants) or HDL cholesterol levels (MD -0.01 mmol/L, 95% CI -0.08 to 0.05; 5 trials, 256 participants) or triglycerides (MD 0.21 mmol/L, 95% CI -0.07 to 0.49; 5 trials, 256 participants) compared to other dietary interventions (moderate-certainty evidence). We are very uncertain about any effect of the vegan dietary intervention on systolic blood pressure (MD 0.02 mmHg, 95% CI -3.59 to 3.62)  or diastolic blood pressure (MD 0.63 mmHg, 95% CI -1.54 to 2.80; 5 trials, 247 participants (very low-certainty evidence)). Only one trial (63 participants) contributed to comparison 3, where there was a lack of evidence for an effect of the vegan dietary intervention on lipid levels or blood pressure compared to other dietary interventions (low- or very low-certainty evidence). Four trials reported on adverse events, which were absent or minor.

AUTHORS' CONCLUSIONS: Studies were generally small with few participants contributing to each comparison group. None of the included studies report on CVD clinical events. There is currently insufficient information to draw conclusions about the effects of vegan dietary interventions on CVD risk factors. The eight ongoing studies identified will add to the evidence base, with all eight reporting on primary prevention. There is a paucity of evidence for secondary prevention.

摘要

背景

饮食在心血管疾病(CVD)的病因中起着主要作用,作为一个可改变的风险因素,是许多预防策略的重点。最近,纯素饮食越来越受欢迎,因此有必要综合现有临床试验证据,以证明其在预防心血管疾病方面的潜力。

目的

确定遵循纯素饮食模式对心血管疾病一级和二级预防的有效性。

检索方法

我们于2020年2月4日检索了以下电子数据库:Cochrane对照试验中心注册库(CENTRAL)、MEDLINE、Embase和科学引文索引核心合集。我们还在2021年1月检索了ClinicalTrials.gov。我们没有设置语言限制。

入选标准

我们选择了针对健康成年人、心血管疾病高风险成年人(一级预防)以及已确诊心血管疾病的成年人(二级预防)的随机对照试验(RCT)。纯素饮食模式不包括肉类、鱼类、蛋类、奶制品和蜂蜜;干预措施可以是饮食建议、提供相关食物或两者兼而有之。对照组接受无干预、最小干预或其他饮食干预。结局包括临床事件和心血管疾病风险因素。我们只纳入了随访期为12周或更长时间的研究,定义为干预期加上干预后随访。

数据收集与分析

两位综述作者独立评估研究是否纳入、提取数据并评估偏倚风险。我们使用GRADE来评估证据的确定性。我们进行了三项主要比较:1. 纯素饮食干预与无干预或最小干预用于一级预防;2. 纯素饮食干预与另一种饮食干预用于一级预防;3. 纯素饮食干预与另一种饮食干预用于二级预防。

主要结果

13项随机对照试验(38篇论文,7项试验注册)和8项正在进行的试验符合我们的纳入标准。大多数试验涉及一级预防:比较1(四项试验,随机分配466名参与者)和比较2(八项试验,随机分配409名参与者)。我们仅纳入了一项二级预防试验用于比较3(随机分配63名参与者)。没有一项试验报告临床终点。其他主要结局包括血脂水平和血压。对于比较1,来自四项试验(449名参与者)的中等确定性证据表明,纯素饮食可能导致总胆固醇(平均差(MD)-0.24 mmol/L,95%置信区间(CI)-0.36至-0.12)和低密度脂蛋白(LDL)胆固醇(MD -0.22 mmol/L,95% CI -0.32至-0.11)略有降低,高密度脂蛋白(HDL)水平略有下降(MD -0.08 mmol/L,95% CI -0.11至-0.04),甘油三酯水平略有升高(MD 0.11 mmol/L,95% CI 0.01至0.21)。高密度脂蛋白和甘油三酯水平的微小变化与预期方向相反。没有证据表明纯素饮食干预对收缩压(MD 0.94 mmHg,95% CI -1.18至3.6;3项试验,374名参与者)和舒张压(MD -0.27 mmHg,95% CI -1.67至1.12;3项试验,372名参与者)有影响(低确定性证据)。对于比较2,没有证据表明纯素饮食干预对总胆固醇水平有影响(MD -0.04 mmol/L,95% CI -0.28至0.20;4项试验,163名参与者;低确定性证据)。与其他饮食干预相比,纯素饮食干预对低密度脂蛋白(MD -0.05 mmol/L,95% CI -0.21至0.11;4项试验,244名参与者)或高密度脂蛋白胆固醇水平(MD -0.01 mmol/L,95% CI -0.08至0.05;5项试验,256名参与者)或甘油三酯(MD 0.21 mmol/L,95% CI -0.07至0.49;5项试验,256名参与者)可能几乎没有或没有影响(中等确定性证据)。我们非常不确定纯素饮食干预对收缩压(MD 0.02 mmHg,95% CI -3.59至3.62)或舒张压(MD 0.63 mmHg,95% CI -1.54至2.80;5项试验,247名参与者,极低确定性证据)有任何影响。只有一项试验(63名参与者)对比较3有贡献,与其他饮食干预相比,没有证据表明纯素饮食干预对血脂水平或血压有影响(低或极低确定性证据)。四项试验报告了不良事件,均未出现或为轻微事件。

作者结论

研究总体规模较小,每个比较组的参与者较少。纳入的研究均未报告心血管疾病临床事件。目前没有足够的信息来得出关于纯素饮食干预对心血管疾病风险因素影响的结论。已确定的八项正在进行的研究将增加证据基础,所有八项研究均报告一级预防情况。二级预防的证据很少。

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索